Welcome to our dedicated page for XOMA Royalty SEC filings (Ticker: XOMA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on XOMA Royalty's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into XOMA Royalty's regulatory disclosures and financial reporting.
Montano Maricel Perea reported acquisition or exercise transactions in this Form 4 filing.
XOMA Royalty Corp reported that Chief Legal Officer Maricel Perea Montano received new equity awards. She was granted 26,289 restricted stock units payable in common stock, which vest in four equal annual installments starting on March 11, 2026, contingent on continued service.
She also received 40,444 performance stock units, each representing a right to one share of common stock. These performance units vest only if the common stock reaches a specified price per share and she remains in service, aligning a portion of her compensation with long-term share performance.
XOMA ROYALTY CORPORATION ownership update: FMR LLC reports beneficial ownership of 1,268,506.14 shares of common stock, representing 10.2% of the class as of 02/27/2026. The filing also notes that Fidelity Contrafund held 773,332 shares, or 6.2%, as of the same date.
The schedule is an amendment (No. 5) and identifies filings and powers of attorney authorizing the submission; Exhibit 99 and related exhibits are referenced for subsidiary and agreement details.
XOMA Royalty Corporation furnished an updated corporate presentation outlining its royalty aggregation business model, portfolio, and preliminary 2025 financial data. The company focuses on acquiring early- to mid‑stage biotech royalty and milestone rights and highlights a diversified portfolio exceeding 100 assets, with more than $140M in milestones received since 2017 and over $2B in potential future milestones.
The presentation’s preliminary 2025 update shows $49–50M in cash received from royalties and milestones and about $133M of cash, cash equivalents and restricted cash as of December 31, 2025. XOMA repurchased and retired 648,048 common shares during 2025 for $16M, with 11,888,489 common shares outstanding as of February 27, 2026. General and administrative expenses for 2025 include roughly $1M tied to ongoing litigation with Janssen Biotech regarding use of XOMA intellectual property, and the company notes that the outcome and any potential recovery are uncertain.
Morgan Stanley and Morgan Stanley Investment Management Inc. filed an amended Schedule 13G reporting significant ownership in XOMA Royalty Corp common stock. They report beneficial ownership of 1,702,545 shares, representing 13.7% of the class, with voting and dispositive power shared through affiliated entities.
The filers state the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of XOMA Royalty Corp.
XOMA Royalty Corporation has completed its acquisition of Generation Bio Co. through a tender offer followed by a merger. XOMA Royalty’s subsidiary first purchased Generation Bio common shares at $4.2913 per share in cash plus one contingent value right (CVR) per share, then merged the subsidiary into Generation Bio.
As of the tender expiration on February 6, 2026, holders had validly tendered 4,722,533 shares, representing about 70% of Generation Bio’s outstanding stock, satisfying the minimum tender condition. Remaining eligible shares were converted into the same cash-and-CVR package, and Generation Bio is now a wholly owned subsidiary of XOMA Royalty.
XOMA Royalty Corporation filed an amended report to give more detail on the legacy assets it acquired with LAVA Therapeutics. These include EGFRd2 (PF-8046052), outlicensed to Pfizer for cancers, and JNJ-89853413, outlicensed to Janssen Biotech for acute myeloid leukemia, both in early clinical trials with Pfizer and Janssen responsible for development and commercialization.
XOMA also acquired LAVA-1266 but does not plan further development and is seeking a sale or other disposition. Former LAVA shareholders received contingent value rights (CVRs) tied to any future monetization of these assets, with 75% of net proceeds payable through the CVRs. XOMA and LAVA previously estimated the CVR value at $0.00 because of the high uncertainty around early-stage oncology programs and limited prospects for LAVA-1266.
XOMA Royalty Corporation is making a leadership change in its finance organization. Effective January 12, 2026, the board appointed Jeffrey Trigilio as Chief Financial Officer, succeeding Thomas Burns, who stepped down from his role on the same date.
Mr. Trigilio will receive an annual base salary of $515,000 and is eligible for a target annual cash bonus equal to 40% of base salary. His compensation package includes an initial grant of 30,000 performance units that vest based on stock price hurdles over a period ending on the earlier of May 18, 2026 or the 2026 annual stockholder meeting, plus a 2026 annual equity grant valued at 180,000 times the closing price of XOMA common stock on the effective date.
The employment agreement provides severance and change-of-control protections, including up to 1.5 times base salary and target bonus, extended health benefits, outplacement services, and accelerated equity vesting in certain termination scenarios. Mr. Burns will receive severance under his existing agreement, acceleration of certain performance stock units, and a consulting role for three months at $16,000 per month to support transition.
XOMA Royalty Corp reported an equity award to its Chief Financial Officer, Jeffrey Trigilio. On 01/12/2026, he was granted 30,000 Performance Stock Units (PSUs) at an exercise price of $0 per unit, recorded as a derivative security held directly.
Each PSU represents a contingent right to receive one share of XOMA common stock. The PSUs vest only if XOMA’s common stock reaches a specified price per share, tying the potential stock delivery to future share-price performance. After this grant, Trigilio beneficially owned 30,000 PSUs.
XOMA Royalty Corp filed an initial insider ownership report for Chief Financial Officer Jeffrey Trigilio. The Form 3 indicates that, at the time of this filing, no securities of XOMA Royalty Corp are beneficially owned. The form is filed by one reporting person, reflecting his role as an officer and providing a baseline disclosure of his current holdings status.
XOMA Royalty Corporation filed a current report to let investors know it has made an updated corporate presentation available as of January 12, 2026. The presentation is attached as Exhibit 99.1 and is intended to provide refreshed information about the company.
The company specifies that the material in Item 7.01, including the presentation, is being furnished rather than filed, meaning it is not subject to certain Exchange Act liability provisions and is not automatically incorporated into other SEC filings unless specifically referenced.